Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Manages mastocytosis. Sold as Intal, Opticrom, Gastrocrom, Nasalcrom. Every FDA application for this active ingredient: 7 branded and 24 generic.
As of Nov 16, 2026, FDA lists 31 applications for Cromolyn Sodium (sold as Intal, Opticrom, Gastrocrom and others), first approved May 28, 1982, with 2 new uses approved and 0 published complete response letters.
First approved: May 28, 1982
Applications: 31
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $13.3M
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Cromolyn Sodium
Part D
$11.9M
+44%
43,895
Gastrocrom
Part D
$1.4M
+30%
89
Cromolyn Sodium
Part B
$57K
-61%
286
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
CROMOLYN 100 MG/5 ML ORAL CONC: $0.368 per MLGeneric · new this year
CROMOLYN 20 MG/2 ML NEB SOLN: $0.950 per MLGeneric · +68% in a year
CROMOLYN 4% EYE DROPS: $0.591 per MLGeneric · +1% in a year
GASTROCROM 100 MG/5 ML CONC: $2.44 per MLBrand · +5% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA